The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
FDA approves Bristol Myers' Opdivo for resectable non-small cell lung cancer, reducing recurrence risk by 42% and showing 70% 18-month event-free survival in patients.
The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
Investor's Business Daily on MSN23h
Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Eli Lilly & Co (LLY – Research ...
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
Health Care Select Sector SPDR Fund ETF (XLV) outperformed the S&P 500 in Q3 2024. Bristol-Myers led growth while Moderna ...
IGM Biosciences shifts focus to autoimmune diseases, reduces oncology research, and appoints former Bristol Myers Squibb ...
The latest health news highlights include Kailera Therapeutics' $400 million funding, potential CVS Health restructuring, ...
Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback